SOLICITATION NOTICE
Q -- Generation and Acquisition of Two Antibody-Cytokine Fusion Proteins for Use Against Neuroblastoma (in-vitro and in-vivo experiments)
- Notice Date
- 5/6/2021 12:09:30 PM
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 325412
— Pharmaceutical Preparation Manufacturing
- Contracting Office
- NIH NCI ROCKVILLE MD 20852 USA
- ZIP Code
- 20852
- Solicitation Number
- 75N91021Q00078
- Response Due
- 5/11/2021 12:00:00 AM
- Archive Date
- 05/26/2021
- Point of Contact
- John Russell, Contract Specialist, Reyes Rodriguez, Contracting Officer
- E-Mail Address
-
John.Russell3@nih.gov, reyes.rodriguez@nih.gov
(John.Russell3@nih.gov, reyes.rodriguez@nih.gov)
- Small Business Set-Aside
- SBA Total Small Business Set-Aside (FAR 19.5)
- Description
- Contracting Office Address: The Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Rockville, MD 20850, UNITED STATES DESCRIPTION: The Department of Health and Human Services (DHHS), National Institutes of Health (NIH), National Cancer Institute (NCI), Center for Cancer Research (CCR), intends to procure, on a sole source basis anti-GD2-antibody-IL-21 and anti-GD2-antibody IL-15 fusion proteins from Creative Biolabs Inc, 45-1 Ramsey Rd, Shirley, New York 11967-4715. The response close date of the notice for this requirement is in accordance with FAR 5.203(b). This acquisition will be processed under FAR Part 12 (Acquisition for Commercial Items) and will be made pursuant to the authority in FAR 13.106-1 (b)(1); and is exempt from the requirements of FAR Part 6. The North American Industry Classification System code is 325412 and the business size standard is 1,250 employees. Creative Biolabs previously supplied anti-GD2-antibody-IL-21 and anti-GD2-antibody IL-15 fusion proteins that have been utilized in ongoing research related to Neuroblastoma, which is a childhood cancer and accounts for 650 new cases a year and 15% of all cancer-related childhood mortalities. As such, in order to avoid any experimental variation purely based on differences in manufacturing processes, it is critical that both of these antibodies be generated by the same vendor in the exact same manner as previously produced. It is for the above reasons; NCI believes that no other vendors can provide the required services in a manner consistent with LTIB�s needs as outlined in the attached Statement of Need. This notice is not a request for competitive quotations. However, if any interested party, especially small business, believes it can meet the attached requirement, it may submit a proposal/quote/capability statement for the Government to consider. The response and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. All responses must be submitted via email to Contract Specialist, John Russell, at John.Russell3@nih.gov by no later than 2:00 PM EST, on May 11, 2021 (05/11/21). A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, Contractors must be registered and have valid certification through SAM.GOV. Reference: 75N91021Q00078 on all correspondence. ****Please review all posting attachments for more details�****
- Web Link
-
SAM.gov Permalink
(https://beta.sam.gov/opp/61ad58643e134fd990c661771392bc66/view)
- Place of Performance
- Address: Bethesda, MD 20892-7511, USA
- Zip Code: 20892-7511
- Country: USA
- Zip Code: 20892-7511
- Record
- SN05993695-F 20210508/210506230114 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |